• Assay Selection Tool

BellBrook Labs

  • Products
    • Transcreener® HTS Assays
      • Transcreener® ADP² Kinase Assay
      • Transcreener® AMP²/GMP² Phosphodiesterase Assay
      • Transcreener® cGAMP cGAS Assay
      • Transcreener® GDP GTPase Assay Kits
      • Transcreener® UDP² Glycosyltransferase Assay
      • Transcreener® EPIGEN SAH Methyltransferase Assay
    • AptaFluor® HTS Assays
      • AptaFluor® SAH Methyltransferase Assay
    • HTS Assays by Target
      • Kinase Assay Kits
      • ATPase Assay Kits
      • cGAS Assay Kits
      • CD39 Assay Kits
      • CD73 Assay Kits – Coming Soon!
      • EZH2 Assay Kits
      • Glycosyltransferase Assay Kits
      • Phosphodiesterase Assay Kits
      • Ligase and Synthetase Assay Kits
      • Methyltransferase Assay Kits
      • GTPase Assay Kits
      • GAP Assay Kits
      • GEF Assay Kits
    • Ordering Information
  • Therapeutics
    • Pipeline
    • Scientific Advisory Board
  • Resources
    • Application Notes
    • Transcreener® Assays – Instrument Compatibility
    • Posters and Presentations
    • Publications
    • Technical Manuals
    • Transcreener® FAQ’s
    • Residence Time Guide
  • Company
    • President’s Message
    • International Distributors
    • Careers
    • Downloads
    • Contact Us
  • Blog
  • MY CART
    No products in cart.

FAK Inhibitors: Thwarting Tumor Growth and Curbing Metastasis

by katie.lowery / Thursday, 20 February 2014 / Published in Emerging Targets

Focal Adhesion Kinase (FAK) is a compelling cancer target as it both aids tumor growth and promotes metastasis.  However, to date, little has been known about the molecular mechanisms behind these relationships.  In a new study, published in the January issue of The Journal of Cell Biology, researchers in David Schlaepfer’s lab at the University of California San Diego Cancer Center, show that specific FAK phosphorylation events contribute to metastasis by promoting vascular permeability in endothelial cells.

Vascular endothelial cadherin (VEC), helps endothelial cells bind together closely, making it harder for cancer cells to spread.  Vascular endothelial growth factor (VEGF), produced in numerous cancers, is VEC’s worst enemy; by binding to and activating the receptor VEGFR-2, VEGF triggers the phosphorylation of VEC, loosening the binds between endothelial cells, and allowing cancer cells to slip through and enter the bloodstream.    

While much remains unknown about the relationship between VEGFR-2 activation and VEC phosphorylation, concurrent FAK accumulation at cell to cell junctions has suggested the protein’s involvement.  

To further explore this relationship between VEGFR-2 activation and FAK, researchers gave a FAK inhibitor to mice with fast-spreading breast cancer and mice with ovarian tumors.   In both cases, the FAK inhibitor prevented phosphorylation of VEC tyrosine 658.  Researchers then injected VEGF into mice with an enzymatically inactive variant of FAK and into control mice.  VGEF prompted phosphorylation of VEC tyrosine 658 in the control mice but not in those containing inactive FAK, suggesting the presence of FAK as crucial to successful VEFR-2 activated VEC phosphorylation.

Furthermore, mice that expressed a kinase dead version of FAK in their endothelial cells had far fewer tumor cells in their lungs than control mice; blocking endothelial FAK curbed metastasis.  

The work, says senior author David Schlaepfer, places FAK in the pathway that controls vascular permeability and further supports the possibility that FAK inhibitors – already being tested in clinical trials due to their ability to restrain tumor growth – provide the added benefit of curbing metastasis.  

Tagged under: Transcreener ADP Kinase Assay

What you can read next

A New Twist to Metastatic Spread
ADP Detection: It’s not all about kinases
Could an Inhibitor of Phosphodiesterase Activity be a Treatment for Alzheimer’s?

Categories

  • Company
  • Emerging Targets
  • Epigenetics
  • HTS Assays
  • Neurodegenerative Diseases
  • News
  • Products
  • Resources
  • Success Stories
  • Uncategorized

Recent Posts

  • CDK12 Activity Assays Find Inhibitors Cancer Treatment

    Finding Inhibitors for a Cancer Target: CDK12 Activity Assays Accelerate the Search

    All systems within our bodies function by means...
  • New Transcreener cGAS Assay

    BellBrook Labs Launches Transcreener cGAS Activity Assay to Accelerate Drug Discovery

    The new Transcreener cGAMP cGAS Assay directly ...
  • Fighting Ovarian Cancer ST3GAL1 Inhibitors

    Helping Fight Ovarian Cancer with ST3GAL1 Inhibitors

    Important functions such as cell–cell recogniti...
  • Scientist Working on TBK1 Inhibitors for Cancer Research

    Using TBK1 Inhibitors to Stop Cancer in Its Tracks

    TBK1 Inhibitors, Autoimmune Disorders, and Canc...
  • ENPP1 Inhibitors Improve Innate Immunity

    ENPP1 Inhibitors, Assays, and Innate Immunity

    The human immune response is incredible. Unlike...

Archives

BellBrook Labs
5500 Nobel Drive, Suite 230
Madison, Wisconsin 53711 USA
(608) 443-2400

info@bellbrooklabs.com

 Copyright © 2019 BellBrook Labs | All Rights Reserved | Privacy Policy | Terms of Use | FCOI | Sitemap

TOP